Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
0.1×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.4×0.0×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0.3×+0.2×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
0.1×0.0×

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$912.8M+54.1%
Enterprise value$904.32M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

Based on the most recent quarter.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's debt-to-assets?
Sana Biotechnology (SANA) reported debt-to-assets of 0.2× in Q1 2026.
How has Sana Biotechnology's debt-to-assets changed year-over-year?
Sana Biotechnology's debt-to-assets decreased by 1.7% year-over-year, from 0.2× to 0.2×.
What is the long-term trend for Sana Biotechnology's debt-to-assets?
Over 5 years (2020 to 2025), Sana Biotechnology's debt-to-assets has grown at a 13.9% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.